文献速递妇科生殖医学

左炔诺孕酮宫内装置的II期前瞻性试验:复杂不典型增生与早期子宫内膜癌的非手术疗法

Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
PubMed 文献 · Am J Obstet Gynecol · 2020-08-15

这项单机构、单臂II期研究评估了左炔诺孕酮宫内装置(52 mg左炔诺孕酮,Mirena)治疗复杂不典型增生或1级子宫内膜样癌的疗效,57例患者中47例可评估,12个月缓解率为83%,复杂不典型增生为90.6%,1级子宫内膜样癌为66.7%,不良事件轻微,生活质量未受负面影响。

要点

  • 左炔诺孕酮宫内装置在复杂不典型增生和1级子宫内膜样癌中显示出显著活性,12个月缓解率为83%。
  • 复杂不典型增生缓解率为90.6%,1级子宫内膜样癌为66.7%,9.5%的患者在初始缓解后复发。
  • 3个月时外源性孕激素效应在缓解者中为96.9%,在无缓解者中为25%(P=.001)。

核心结论

  • 左炔诺孕酮宫内装置在复杂不典型增生和1级子宫内膜样癌中具有显著活性,但有一部分患者表现出原发性孕激素抵抗。
  • 已识别出可能与治疗抵抗相关的潜在生物标志物,需要进一步探索。

研究设计与样本

  • 单机构、单臂、II期研究,评估左炔诺孕酮宫内装置(52 mg左炔诺孕酮,Mirena)治疗复杂不典型增生或1级子宫内膜样癌患者。
  • 共治疗57例患者(21例子宫内膜癌,36例复杂不典型增生),中位年龄48.0岁,中位体重指数45.5 kg/m2。
  • 主要终点为12个月时的病理缓解率,包括完全或部分缓解;同时评估生活质量和毒性。
  • 在基线和3个月时进行增殖标志物、激素调节基因和wingless相关整合位点通路活化的分子分析。

主要发现

  • 47例可评估患者中,12个月缓解率为83%(90%可信区间,72.7-90.3),其中37例完全缓解(8例子宫内膜癌;29例复杂不典型增生),2例部分缓解(2例子宫内膜癌),3例疾病稳定(2例子宫内膜癌;1例复杂不典型增生),5例疾病进展(3例子宫内膜癌;2例复杂不典型增生)。
  • 按组织学分层后,复杂不典型增生的缓解率为90.6%,1级子宫内膜样癌为66.7%。
  • 4例患者(9.5%)在初始缓解后出现复发。
  • 不良事件轻微,主要为不规则出血和痉挛;生活质量未受负面影响。
  • 3个月时,外源性孕激素效应在缓解者中为96.9%(31/32),在无缓解者中为25%(2/8)(P=.001);无缓解者基线增殖(Ki67)较高且dickkopf homolog 3基因表达较低(P=.023和P=.030);无缓解者与缓解者相比,分泌型卷曲相关蛋白1、卷曲类受体8和视网膜醛脱氢酶2的变化显著不同。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of complex atypical hyperplasia and early-stage endometrioid endometrial cancer is increasing, in part owing to the epidemic of obesity, which is a risk factor tightly linked to the development of endometrial hyperplasia and cancer. The standard upfront treatment for complex atypical hyperplasia and early-stage endometrial cancer is hysterectomy. However, nonsurgical treatment of early-stage endometrial neoplasia may be necessary owing to medical comorbidities precluding surgery or desired future fertility. OBJECTIVE: This study aimed to evaluate the efficacy of the levonorgestrel intrauterine device to treat complex atypical hyperplasia and grade 1 endometrioid endometrial carcinoma. STUDY DESIGN: A single-institution, single-arm, phase II study of the levonorgestrel intrauterine device (52 mg levonorgestrel, Mirena) was conducted in patients with complex atypical hyperplasia or grade 1 endometrioid endometrial cancer. The primary endpoint was pathologic response rate at 12 months, including complete or partial response. Quality of life and toxicity were assessed. Molecular analyses for proliferation markers, hormone-regulated genes, and wingless-related integration site pathway activation were performed at baseline and 3 months. RESULTS: A total of 57 patients were treated (21 endometrial cancer, 36 complex atypical hyperplasia). The median age was 48.0 years, and the median body mass index was 45.5 kg/m2. Of the 47 evaluable patients, 12-month response rate was 83% (90% credible interval, 72.7-90.3)-37 were complete responders (8 endometrial cancer; 29 complex atypical hyperplasia), 2 were partial responders (2 endometrial cancer), 3 had stable disease (2 endometrial cancer; 1 complex atypical hyperplasia), and 5 had progressive disease (3 endometrial cancer; 2 complex atypical hyperplasia). After stratification for histology, the response rate was 90.6% for complex atypical hyperplasia and 66.7% for grade 1 endometrioid endometrial cancer. Notably, 4 patients (9.5%) experienced relapse after the initial response. Adverse events were mild, primarily irregular bleeding and cramping. Quality of life was not negatively affected. At 3 months, exogenous progesterone effect was present in 96.9% of responders (31 of 32) vs 25% of nonresponders (2 of 8) (P=.001). Nonresponders had higher baseline proliferation (Ki67) and lower dickkopf homolog 3 gene expression than responders (P=.023 and P=.030). Nonresponders had significantly different changes in secreted frizzled-related protein 1, frizzled class receptor 8, and retinaldehyde dehydrogenase 2 compared with responders. CONCLUSION: The levonorgestrel intrauterine device has a substantial activity in complex atypical hyperplasia and grade 1 endometrioid endometrial cancer, with a modest proportion demonstrating upfront progesterone resistance. Potential biomarkers were identified that may correlate with resistance to therapy; further exploration is warranted.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Westin SN, Fellman B, Sun CC, et al. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2020. PMID: 32805208. doi:10.1016/j.ajog.2020.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。